SPAR
NSE: SPAR

Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Key Statistics

Investment Rating

  • Master Rating:
  • Sun Pharma Advd.Resh. has an operating revenue of Rs. 143.72 Cr. on a trailing 12-month basis. An annual revenue de-growth of -44% needs improvement, Pre-tax margin of -148% needs improvement, ROE of -651% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 21 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Synopsis

NSE-Medical-Biomed/Biotech

Sun Pharma Advanced is involved in the business activities of Research and experimental development on natural sciences and engineering. Company’s Total Operating Revenue is Rs. 252.96 Cr. and Equity Capital is Rs. 26.21 Cr. for the Year ended 31/03/2021. Sun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L73100GJ2006PLC047837 and registration number is 047837.
  • Market Cap
  • 5,916
  • Sales
  • 144
  • Shares in Float
  • 8.43
  • No of funds
  • 67
  • Yield
  • Book Value
  • 189.22
  • U/D Vol ratio
  • 1.1
  • LTDebt / Equity
  • Alpha
  • -0.12
  • Beta
  • 1.59

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 69.09%
  • 69.09%
  • 68.1%
  • Mutual Funds
  • 0.24%
  • 0.24%
  • 0.02%
  • Foreign Portfolio Investors
  • 2.4%
  • 2.38%
  • 2.51%
  • Financial Institutions/ Banks
  • Individual Investors
  • 16.46%
  • 14.73%
  • 16.94%
  • Others
  • 11.81%
  • 13.56%
  • 12.43%

Management

  • Name
  • Designation
  • Mr. Dilip S Shanghvi
  • Chairman
  • Dr. T Rajamannar
  • Non Executive Director
  • Dr. Robert J Spiegel
  • Non Executive Director
  • Mr. Sudhir V Valia
  • Non Executive Director
  • Ms. Bhavna Doshi
  • Independent Director
  • Dr. Ferzaan Engineer
  • Independent Director

Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

FAQs

What is Share Price of ?

share price is ₹ As on 13 August, 2022 | 06:19

Q1FY23